North America Pancreatic Cancer Precision Medicine Market Size & Outlook
North America pancreatic cancer precision medicine market, 2018-2030 (US$M)
Related Markets
North America pancreatic cancer precision medicine market highlights
- The North America pancreatic cancer precision medicine market generated a revenue of USD 281.9 million in 2024.
- The market is expected to grow at a CAGR of 18.6% from 2025 to 2030.
- In terms of segment, targeted therapy was the largest revenue generating therapeutic approach in 2024.
- Chemotherapy-Precision Combinations is the most lucrative therapeutic approach segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2025 to 2030.
North America data book summary
| Market revenue in 2024 | USD 281.9 million |
| Market revenue in 2030 | USD 779.0 million |
| Growth rate | 18.6% (CAGR from 2025 to 2030) |
| Largest segment | Targeted therapy |
| Fastest growing segment | Chemotherapy-Precision Combinations |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations, Other Therapeutic Approaches |
Other key industry trends
- In terms of revenue, North America region accounted for 42.9% of the global pancreatic cancer precision medicine market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 450.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pancreatic Cancer Precision Medicine Market Scope
Pancreatic Cancer Precision Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America pancreatic cancer precision medicine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer precision medicine market will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 66.37% in 2024. Horizon Databook has segmented the North America pancreatic cancer precision medicine market based on targeted therapy, immunotherapy, chemotherapy-precision combinations, other therapeutic approaches covering the revenue growth of each sub-segment from 2018 to 2030.
North America pancreatic cancer precision medicine market dominated the global market with a revenue share of 42.9% in 2024, propelled by high incidence rates requiring effective treatments.
Substantial research and development investments in genetic profiling and targeted therapies further drive market expansion. Supportive regulatory frameworks facilitate the approval and adoption of innovative precision medicine treatments, enhancing market growth and patient outcomes.
Reasons to subscribe to North America pancreatic cancer precision medicine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America pancreatic cancer precision medicine market databook
-
Our clientele includes a mix of pancreatic cancer precision medicine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America pancreatic cancer precision medicine market , including forecasts for subscribers. This continent databook contains high-level insights into North America pancreatic cancer precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America pancreatic cancer precision medicine market size, by country, 2018-2030 (US$M)
North America Pancreatic Cancer Precision Medicine Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
